Swiss National Bank
RARE icon

Swiss National Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Swiss National Bank’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.58M Hold
171,052
– – ﹤0.01% 1538
2025
Q4 		$3.93M Buy
171,052
+6,100
+4% +$201K ﹤0.01% 1488
2025
Q3 		$4.96M Buy
164,952
+3,900
+2% +$117K ﹤0.01% 1338
2025
Q2 		$5.86M Hold
161,052
– – ﹤0.01% 1189
2025
Q1 		$5.83M Sell
161,052
-2,100
-1% -$87.4K ﹤0.01% 1176
2024
Q4 		$6.86M Buy
163,152
+4,000
+3% +$198K ﹤0.01% 1132
2024
Q3 		$8.84M Buy
159,152
+13,300
+9% +$677K 0.01% 1003
2024
Q2 		$5.99M Hold
145,852
– – ﹤0.01% 1154
2024
Q1 		$6.81M Buy
145,852
+4,300
+3% +$203K ﹤0.01% 1106
2023
Q4 		$6.77M Sell
141,552
-14,100
-9% -$547K 0.01% 1098
2023
Q3 		$5.55M Buy
155,652
+2,800
+2% +$111K ﹤0.01% 1218
2023
Q2 		$7.05M Buy
152,852
+9,100
+6% +$422K ﹤0.01% 1102
2023
Q1 		$5.76M Sell
143,752
-16,900
-11% -$725K ﹤0.01% 1166
2022
Q4 		$7.44M Buy
160,652
+3,100
+2% +$122K 0.01% 1071
2022
Q3 		$6.52M Buy
157,552
+2,300
+1% +$118K ﹤0.01% 1120
2022
Q2 		$9.26M Buy
155,252
+2,100
+1% +$129K 0.01% 960
2022
Q1 		$11.1M Buy
153,152
+11,300
+8% +$786K 0.01% 964
2021
Q4 		$11.9M Buy
141,852
+200
+0.1% +$16.3K 0.01% 913
2021
Q3 		$12.8M Buy
141,652
+1,500
+1% +$136K 0.01% 878
2021
Q2 		$13.4M Sell
140,152
-3,400
-2% -$354K 0.01% 867
2021
Q1 		$16.3M Buy
143,552
+13,400
+10% +$1.82M 0.01% 753
2020
Q4 		$18M Buy
130,152
+1,500
+1% +$178K 0.01% 682
2020
Q3 		$10.6M Buy
128,652
+5,900
+5% +$489K 0.01% 785
2020
Q2 		$9.6M Buy
122,752
+16,300
+15% +$1.08M 0.01% 791
2020
Q1 		$4.73M Buy
106,452
+1,600
+2% +$83.1K 0.01% 966
2019
Q4 		$4.48M Buy
104,852
+2,000
+2% +$82.5K ﹤0.01% 1229
2019
Q3 		$4.4M Buy
102,852
+3,200
+3% +$174K ﹤0.01% 1173
2019
Q2 		$6.33M Buy
99,652
+1,400
+1% +$89.1K 0.01% 973
2019
Q1 		$6.82M Buy
98,252
+14,000
+17% +$800K 0.01% 912
2018
Q4 		$3.66M Buy
84,252
+2,200
+3% +$120K ﹤0.01% 1169
2018
Q3 		$6.26M Hold
82,052
– – 0.01% 976
2018
Q2 		$6.31M Buy
82,052
+4,400
+6% +$284K 0.01% 954
2018
Q1 		$3.96M Buy
77,652
+7,700
+11% +$388K ﹤0.01% 1190
2017
Q4 		$3.24M Buy
69,952
+2,700
+4% +$132K ﹤0.01% 1330
2017
Q3 		$3.58M Buy
67,252
+1,200
+2% +$71.1K ﹤0.01% 1240
2017
Q2 		$4.1M Buy
66,052
+2,100
+3% +$127K ﹤0.01% 1114
2017
Q1 		$4.33M Buy
63,952
+2,400
+4% +$183K 0.01% 1062
2016
Q4 		$4.33M Buy
61,552
+1,500
+2% +$106K 0.01% 1053
2016
Q3 		$4.26M Sell
60,052
-300
-0.5% -$19.1K 0.01% 1009
2016
Q2 		$2.95M Buy
60,352
+16,085
+36% +$1.04M ﹤0.01% 1211
2016
Q1 		$2.7M Buy
44,267
+8,900
+25% +$582K 0.01% 1248
2015
Q4 		$3.97M Buy
35,367
+500
+1% +$50K 0.01% 899
2015
Q3 		$3.36M Buy
34,867
+9,467
+37% +$1.08M 0.01% 994
2015
Q2 		$2.6M Hold
25,400
– – 0.01% 1148
2015
Q1 		$1.58M Buy
25,400
+6,200
+32% +$344K ﹤0.01% 1457
2014
Q4 		$842K Buy
19,200
+12,900
+205% +$591K ﹤0.01% 1831
2014
Q3 		$357K Hold
6,300
– – ﹤0.01% 2274
2014
Q2 		$283K Buy
+6,300
New +$259K ﹤0.01% 2406

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Swiss National Bank's RARE Position: Q1 2026 in Review

Swiss National Bank held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 171,052 shares worth $3.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Swiss National Bank first reported a position in RARE in Q2 2014 and has held it in 48 quarters since. The position peaked at $18M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Swiss National Bank held 171,052 shares of Ultragenyx Pharmaceutical worth $3.58M as of Q1 2026.
  • Swiss National Bank left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1538 holding.
  • Swiss National Bank first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and has held it in 48 quarters since.
  • Swiss National Bank's Ultragenyx Pharmaceutical position peaked at $18M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.